Cited by 212Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 204 of the 206 references it cites were found in a registry or an index.

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

Open access

Song, Yanlin, Bi, Zhenfei, Liu, Yu, Qin, Furong, Wei, Yuquan, Wei, Xiawei·2023·Genes & Diseases

DOI 10.1016/j.gendis.2022.05.006PMC PMC10066287

Open this paper in CoChat — free account

Abstract

Molecular target inhibitors have been regularly approved by Food and Drug Administration (FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and metabolism. The RAS-RAF-MEK-ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation, survival, and differentiation. The aberrant activation of the RAS-RAF-MEK-ERK signaling pathway induces tumors. About 33% of tumors harbor RAS mutations, while 8% of tumors are driven by RAF mutations. Great efforts have been dedicated to targeting the signaling pathway for cancer treatment in the past decades. In this review, we summarized the development of inhibitors targeting the RAS-RAF-MEK-ERK pathway with an emphasis on those used in clinical treatment. Moreover, we discussed the potential combinations of inhibitors that target the RAS-RAF-MEK-ERK signaling pathway and other signaling pathways. The inhibitors targeting the RAS-RAF-MEK-ERK pathway have essentially modified the therapeutic strategy against various cancers and deserve more attention in the current cancer research and treatment.

Integrity signals

Registry

Crossref · 10.1016/j.gendis.2022.05.006

Cites

204 of 204 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,118
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244

Flagged first, then by citations

Show all 206 references

2 of the 206 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 212

Platinum-Paeonol Complexes as ERK Inhibitors To Restrain Melanoma and Relieve Cancer Pain
Tan, Y., Chen, Y., Cai, L., Tong, M., Wang, Y., Guo, Z., & Wang, X. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02901 · Cited by 4
The Role of lncRNAs in Pig Muscle in Response to Cold Exposure
Zhang, D., Wang, L., Wang, W., & Liu, D. (2023) · Genes · doi:10.3390/genes14101901 · Cited by 4
A comprehensive review of RAF kinase: advances in inhibition strategies for drug development
Kahvecioglu, D. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.142206 · Cited by 4
BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer
Clarkson, E., & Lewis, A. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70064 · Cited by 6
Quantifying cancer- and drug-induced changes in Shannon information capacity of RTK signaling
Nałęcz‐Jawecki, P., Roth, L., Grabowski, F., Li, S., Kochańczyk, M., Bugaj, L. J., & Lipniacki, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-23075-y · Cited by 4
A potent dual inhibitor targeting COX-2 and HDAC of acute myeloid leukemia cells
Qin, X., Wang, X., Yang, C., Wang, F., Fang, T., Gu, D., Guo, Q., Meng, Q., Liu, W., & Lu, Y. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11000-w · Cited by 4
Unveiling the HSF1 Interaction Network: Key Regulators of Its Function in Cancer
Vladimirova, S. A., Kokoreva, N. E., Guzhova, I. V., Alhasan, B. A., Margulis, B. A., & Nikotina, A. D. (2024) · Cancers · doi:10.3390/cancers16234030 · Cited by 5
SphK2 promotes the progression of Helicobacter pylori-positive gastric cancer by regulating the Ras/MEK/ERK pathway
Wang, D., Sun, L., Niu, X., Ren, L., & Yang, X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151396 · Cited by 4
Reversible SAHH inhibitor ameliorates MIA-induced osteoarthritis of rats through suppressing MEK/ERK pathway
Fan, S.-H., Chang, Y., Xiong, X.-Y., Xiang, M., Yuan, W., Yang, X., Wei, W.-H., Chen, L., Cheng, M.-N., Zhu, F., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115975 · Cited by 4
Different effects of crizotinib treatment in two non‐small cell lung cancer patients with SDC4 :: ROS1 fusion variants
Ohishi, Y., Nakanishi, Y., Hirotani, Y., Suzuki, A., Tanino, T., Nishimaki‐Watanabe, H., Kobayashi, H., Nozaki, F., Ohni, S., Tang, X., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15168 · Cited by 4
Discovery of Yersinia LcrV as a novel biased agonist of formyl peptide receptor 1 to bi-directionally modulate intracellular kinases in triple-negative breast cancer
Ge, Y., Guan, H., Li, T., Wang, J., Ying, L., Guo, S., Lu, J., Ye, R. D., & Wu, G. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.030 · Cited by 3
RRM2 regulates the high expression of PD-L1 via the ERK signaling pathway to play a cancer-promoting role in cervical cancer
Abuduhailili, X., Feng, Y., Lu, R., Li, Y., & Wang, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156114 · Cited by 3
Plastic poisoning the next generation: omics-anchored partial-adverse outcome pathway affords a glimpse into how gestational polystyrene nano-plastics exposure compromises adult male offspring reproduction.
Zhang, R.-X., Wang, H., Zhao, M., Zhang, Y., Xue, J., Luo, X., Xie, J., Zhang, R.-Y., Yang, X., Ge, W.-L., et al. (2026) · Environment International · doi:10.1016/j.envint.2026.110126 · Cited by 3
Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
Basilicata, M., Terrano, V., DʼAurelio, A., Bruno, G., Troiani, T., Bollero, P., & Napolitano, S. (2024) · Healthcare · doi:10.3390/healthcare12010105 · Cited by 6
ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells
Takasaki, T., Hamabe, Y., Kenta, T., Khandakar, G. I., Ueda, T., Okada, H., Sakai, K., Nishio, K., Tanabe, G., & Sugiura, R. (2024) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2024/7683793 · Cited by 3
Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications
Khattab, S., Berisha, A., Baran, N., & Piccaluga, P. P. (2025) · Biomedicines · doi:10.3390/biomedicines13010202 · Cited by 4
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
Emami, A., Sharif, P. M., & Rezaei, N. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500426 · Cited by 3
Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers
Mughees, M., Tacam, M. J., Tan, A. W., Pitner, M. K., Iles, L. R., Hu, X., Villodre, E. S., Debeb, B. G., Kogawa, T., Lim, B., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0593 · Cited by 3
Unravelling the role of melanogenesis in melanoma: oncogenic crosstalk and therapeutic prospects
Bhat, A. M., Bhat, I. A., & Abdullah, S. T. (2025) · Archives of Dermatological Research · doi:10.1007/s00403-025-04400-x · Cited by 3
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1
Parker, H. G., Harris, A. C., Plassais, J., Dhawan, D., Kim, E., Knapp, D. W., & Ostrander, E. A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00591-0 · Cited by 5
Navigating the complexity of BRAF mutations in non-small cell lung cancer: current insights and future prospects
Ibrahim, S., Shenoy, S., Kateel, R., Hegde, S., Parida, A., & Samantaray, L. (2024) · Multidisciplinary Respiratory Medicine · doi:10.5826/mrm.2024.992 · Cited by 3
Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
Biersack, B., Nitzsche, B., & Höpfner, M. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.125 · Cited by 4
Combining AdipoRon with Paclitaxel Unveils Synergistic Potential in Non-Small Cell Lung Cancer Cells via AMPK-ERK1/2 Signaling
Kafeel, S., Palmiero, G., Salzillo, A., Ragone, A., Naviglio, S., & Sapio, L. (2025) · Cells · doi:10.3390/cells14080602 · Cited by 4
Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression DataPreprint
Karathanasis, N., & Spyrou, G. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.623149 · Cited by 3
Exploration and biological evaluation of 20‐vinyl pregnenes: A step forward toward selective modulators of the estrogen receptor α signaling for breast cancer treatment
Malakhova, V., Scherbakov, A. M., Sorokin, D. V., Leanavets, H., Dzichenka, Y. U., Zavarzin, I. V., & Volkova, Y. A. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202300651 · Cited by 2
The Actin Motor Protein Myosin 6 Contributes to Cell Migration and Expression of GIPC1 and Septins in Breast Cancer Cells
Izdebska, M., Arendt, W., Hałas‐Wiśniewska, M., Zakrzewski, P., Lenartowski, R., & Lenartowska, M. (2024) · Cancer Management and Research · doi:10.2147/cmar.s479151 · Cited by 2
Reactive oxygen species (ROS) induce the gametogenesis through regulating the expression of genes related to ontogenetic stage in gametophyte of Saccharina japonica
Jin, H., Xing, Q., Yu, Y., Xu, Y., Qin, Y., Liao, X., & Liu, F. (2025) · Algal Research · doi:10.1016/j.algal.2025.104254 · Cited by 2
Nicotinic Acetylcholine Receptor Pathways in Cancer: From Psychiatric Clues to Therapeutic Opportunities
Azadi, M. H., Pazooki, P., Ajdary, S., & Shafaroodi, H. (2025) · Cancer Reports · doi:10.1002/cnr2.70387 · Cited by 2
Prognostic Impact of RAS and TP53 Mutation Profiles in Metastatic Colorectal Cancer
Duygulu, M. E., Karaman, E., Karakullukçu, S., & Munğan, S. (2026) · Medicina · doi:10.3390/medicina62010136 · Cited by 2
MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC
Li, C., Deng, S., Zhuang, M., Li, T., Lin, L., Zheng, L., Lin, K., Li, D., & Chen, F. (2026) · Oncogene · doi:10.1038/s41388-026-03795-9 · Cited by 2
Kinase Inhibitors: A Promising Approach for Targeted Cancer Therapy
Sharma, V., Kumar, A., Gour, R., & Kumar, K. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.202503338 · Cited by 2
Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress
Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 3
Regulation and function of the RSK family in colorectal cancer
Wang, Z., Han, X., Lei, Z., Shi, C., Wang, Y., & Guo, L. (2024) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2023.120 · Cited by 2
In silico–guided synthesis of a new, highly soluble, and anti‐melanoma flavone glucoside: Skullcapflavone II‐6′‐O‐β‐glucoside
Chang, T., Ding, H., Wang, T., Wu, J., Tsai, P., Suratos, K. S., Tayo, L. L., Liu, G., & Ting, H. (2024) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2685 · Cited by 2
Areca catechu L. Extract Inhibits Colorectal Cancer Tumor Growth by Modulating Cell Apoptosis and Autophagy
Tsai, M.-H., Chen, C., Chen, C.-L., Lee, M., Wu, L.-C., Hsu, Y., Hsiao, C.-Y., Lee, C.-T., Pi, K.-L., & Su, L. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020128 · Cited by 2
Functional Role of Protein Phosphatase-6 (PPP6c): Regulation of Expression and Modulation of Activity
Ruksha, T. G., & Аксененко, М. Б. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673310356240630103257 · Cited by 2
PLCH1 overexpression promotes breast cancer progression and predicts poor prognosis through the ERK1/2-EGR1 axis
Li, J., Jiang, F., Wang, C., Sun, P., Song, L., & Liu, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1577114 · Cited by 2
Peroxiredoxin 6: A Regulatory Target in Cellular Senescence and Age-Related Diseases
Wang, H., Zhao, Y., Zhou, F., Chen, F., Chen, T., Wang, J., Liu, H., Sun, C., Zhou, R., Hu, W. M., et al. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0793 · Cited by 3
Current Understanding on Impact of Kirsten Rat Sarcoma Viral Oncogene Mutation on Colorectal Cancer: A Review
Pakhira, S., Samanta, P., Ghosh, R., Mondal, M., Biswas, S., Sarkar, R., Bhowmik, A., Saha, P., & Hajra, S. (2024) · Journal of Current Oncological Trends · doi:10.4103/jcot.jcot_3_24 · Cited by 1
Discovery of 2-Amino-7-Amide Quinazoline Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Extracellular Signal-Regulated Kinase 1/2
Zhang, P., Zhang, Y., Sun, Y., Chen, Y., Cao, X. M., He, Y., Tan, Y., Zhang, Z., Deng, S., Zhou, W., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01055 · Cited by 1
Mechanism validation of the saponins from American ginseng in antagonizing chronic heart failure
Tian, J., Tang, M., Geng, Y., Zhang, B., Cai, G., Li, J., Tao, Y., Gong, J., & Yang, Z. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107170 · Cited by 1
Nanotherapeutic formulations of enzyme inhibitors targeting cancer and neuroinflammation: An updated review
Liu, Y., Thiruvengadam, M., Arcot, R., Shariati, M. A., Edis, Z., Chung, I.-M., Liu, S., & Xi, Q. (2025) · Industrial Crops and Products · doi:10.1016/j.indcrop.2025.121803 · Cited by 1
Self-citation
A novel disulfidptosis-related mRNA signature predicts prognosis and therapeutic response in lung squamous cell carcinoma
Bai, W., Jiang, N., Deng, Y., Tang, X., Zhang, F., Niu, S., Yao, Y., Zhou, Y., Chen, K., Li, L., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03920-6 · Cited by 1
Growth hormone - releasing hormone antagonists induce autophagy in cancer cells
Sigdel, M., Fakir, S., Sarker, M. M. R., & Barabutis, N. (2025) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2025.101668 · Cited by 1
Hsa-miR-181a-5p Enhances the Chemosensitivity of Breast Cancer Cells to Tamoxifen by Regulation of the OSBPL3/RAS Signaling Pathway
Lin, J., Li, X., Qu, X., Li, C., Cao, S., & Fu, X. (2025) · Cureus · doi:10.7759/cureus.94996 · Cited by 1
Low GOPC mRNA expression is a novel candidate associated with increased risk of acute myeloid leukemia
Kadhim, T. A., Ghamyes, R. R., Azeez, D. A., Bashi, M. A., Alsodani, A. A., Al-Qayyim, M. K., Kadhim, N. T., Nijeeb, R. A., Bani-Wais, D. F. N., & Ad'hiah, A. H. (2025) · Human Gene · doi:10.1016/j.humgen.2025.201516 · Cited by 1
Mechanistic insights into marine-derived PDE6D inhibitors disrupting prenyl-binding to modulate leukemia-associated RAS trafficking
Alam, P., Akhtar, A., Ahmed, S., & Hasan, Z. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108821 · Cited by 2
A comprehensive review about the anticancer properties of gigantol
Chowdhury, R., Al‐Qaaneh, A. M., Bhuia, M. S., Al-Azzawi, M. A., Rakib, A. I., El-Shazly, M., Islam, M. T., & El‐Nashar, H. A. S. (2025) · Natural Product Research · doi:10.1080/14786419.2025.2600500 · Cited by 1
Transcriptomic and proteomic assessment of radiation injury and dose-rate dependency in white blood cells
Subedi, S. D., Khilji, S., Vuong, N. Q., Kral, C., Fulton, K. M., Baay, I., Twine, S. M., Wilkins, R. C., Williams, A., Kumarathasan, P., et al. (2026) · Journal of Radiological Protection · doi:10.1088/1361-6498/ae4be9 · Cited by 1
Galangin Overcomes Gefitinib and Sotorasib Resistance in Non-small Cell Lung Cancer by Inhibiting Efferocytosis
Su, T.-H., Cao, J., Ding, X.-X., Guo, X.-Z., Chen, A.-L., Zhou, W.-H., Deng, P., Luo, P., Chen, Y., & Wang, F. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c17222 · Cited by 2
Vitamin D3 in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway
Zhao, S., Shan, C., Zhong, Y., Wan, D., Xin, Y., & Wang, W. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103551 · Cited by 1
Novel benzofuran–1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies
Serag, M. I., Elnagar, M. R., Ewes, W. A., Abdel‐Aziz, A. A. ‐., Brogi, S., Ghabbour, H. A., Takla, F. N., Hamdi, A., El-Shafey, H. W., & El‐Azab, A. S. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118766 · Cited by 1
The role of Nir2, a lipid-transfer protein, in regulating endothelial cell functions
Polianskyte-Prause, Z., Arora, A., Taskinen, J., Chaurasiya, V., Keskitalo, S., Tuhkala, A., Hilska, I., Varjosalo, M. T., & Olkkonen, V. M. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119926 · Cited by 1
Unraveling the mechanisms of antitumor action of Sophora flavescens flavonoids via network pharmacology and molecular simulation
Guo, Z., Dong, G., Liu, X., Chen, L., Yang, H., & Wang, Z. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00338-0 · Cited by 1
Clinical application of the MEK inhibitor trametinib in dogs with oral squamous cell carcinoma
Katt, W. P., Balkman, C. E., Byron, M., Carney, P. C., Chrostek, E., Drozd, M. E., Duhamel, G. E., Fiani, N., Hume, K. R., King, A. L., et al. (2025) · Veterinary oncology. · doi:10.1186/s44356-025-00042-3 · Cited by 1
Hailey-Hailey disease models identify synergistic therapeutic effects of MEK and ROCK inhibitionPreprint
Ayers, J., Parihar, A., Tiwaa, A., Aravind, A., Martin, M. C., Pence, K., Tam, C. J., Sutter, N., Skruber, K., Sarkar, M. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.20.726679 · Cited by 2
Studies of Erk1/2 with Respect to Tumor Aggressiveness in B16f10 Murine Melanoma Cells
Moulik, S., Karmakar, S., Basu, A., Mukherjee, S., Neeraja, R. , & -, A. C. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i01.1733
RUVBL1/2 Complex in Cancer: Emerging Mechanisms and Therapeutic Opportunities
Akdemir, B., Gungor, M. Z., & Şentürk, Ş. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_347
Clinical Studies and Small Molecule Inhibitors for RASopathy Treatment
Gross, A. M., Yohe, M. E., & Widemann, B. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_41
First Insight into the Mutational Landscape of BRAF and KRAS Genes in Lung Cancer Patients from Morocco
Founini, Y. E., Guessous, F., Dehbi, H., Karkouri, M., Attaleb, M., Mzibri, M. E., Boubia, S., Ridaï, M., & Chaoui, I. (2024) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921347352241112105112
Lupeol: Bioactivity-guided cytotoxic principle from Hymenocardia acida Tul. (Phyllantaceae) suppresses signaling pathways via polypharmacology antagonism
Adedokun, O. A., Ayinde, B. A., Maggi, F., & Barboni, L. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.12.007
Lasalocid inhibits melanoma by down-regulating FOXM1 through PI3K/AKT and JNK/P38 MAPK pathways
Yuan, Q., Jiang, H., Zhu, M., Chu, Y., Zhang, Y., Bie, J., & Li, L. (2024) · Journal of Cancer · doi:10.7150/jca.101798
The long isoform of PRLR promotes tumor progression by regulating CDK6 through MAPK signal pathway in SHH medulloblastomaPreprint
Sun, Z., Li, H., Peng, Y., Liu, Y., Wang, Y., Wang, J., Liu, X., Zheng, D., Liang, H., & Chang, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-5667015/v1
Self-citation
TM7SF2 as a Potential Biomarker in Colorectal Cancer: Implications for Metastasis
Hong, I., Kim, S., Lee, M., Han, S. H., Kim, H. C., Chu, C. W., Kim, S. G., Kim, M.-K., Kim, C., Kang, D. H., et al. (2025) · Current Oncology · doi:10.3390/curroncol32020114
Targeting RAS and associated proteins
Müller, M. P., Goody, R. S., & Rauh, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00008-x
Thyroid cancer: Clinical landscape
Prajapati, V., Roy, S. D., Sahu, Y., Roy, D., Tanna, S., & Patel, J. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30219-0.00010-8
Independent and synergistic roles of MEK-ERK1/2 and PKC pathways in regulating functional changes in vascular tissue following flow cessation
Kazantzi, S., Edvinsson, L. I., & Haanes, K. A. (2025) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2025.100300
Immunotherapy-Based Combination Therapy for the Successful Treatment of Coexisting Primary and Axillary Accessory Breast Cancers: A Case Report
Tanaka, Y., & Suzuki, Y. (2025) · Cureus · doi:10.7759/cureus.83340
A computational framework for the design and development of ERK2 and multi-target ERK2/HDAC inhibitors
Čebzan, A., Ružić, D., Djoković, N., Stanković, B., & Nikolic, K. M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108543
Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer
Charbel, N., Aramouni, K., Sater, S., & Kreidieh, F. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100568
SIN1 facilitates glioma progression and is associated with the KRAS/ERK pathway
Cao, H., Yan, Z., Li, M., Wang, J., Zhang, H., Cheng, Y., Sun, J., Ren, J., & Yang, D. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05166-y
HOXB7 drives bladder cancer progression via H-Ras/ERK signaling: a potential therapeutic target and prognostic biomarker
Chen, X., Jiang, K., Chen, K., An, Y., Wang, Q., Chen, X., Zhāng, P., Zhong, Q., & Sun, F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1645803
Medicinal chemistry perspective of ERK1/2 inhibitors in cancer treatment: an updated patent review (2019–present)
Singh, A. K., Chauhan, A., Prajapati, V., Kumar, A., Singh, H., Verma, A., & Kumar, P. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2575028
Critical regulatory roles of non-coding RNAs in driving cancer sensitivity to Carmustine: a systematic review
Rahimi, S. M., & Bagheri, A. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04562-5
Identification of phosphofructokinase-1 as a target of Chinese olive fruit (Canarium album L.) extract in colorectal cancer cells: Mechanistic insights into cellular energy stress-induced apoptosis
Lian, G.-T., Chan, C.-W., Lee, H., Liao, Y., Liao, C., & Hsieh, S. (2026) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2026.102684
An aggressive and recurrent pediatric ganglioglioma with unusual genotype: A rare case report
Londhe, M. M., Chamaria, R. M., Gurwale, S. G., Gore, C. R., & Jeeson, J. C. (2026) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_742_24
The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway
Yang, Z., Wei, W. J., Nie, D., Zhang, M., & Chen, Q. (2026) · Future Science OA · doi:10.1080/20565623.2026.2615619
Sulfasalazine induces ferroptosis by regulating the PIAS3/JAK1/STAT3 pathway to prevent brain metastases of hepatocellular carcinoma
Li, W. L., Wang, P., & Zhang, Z. (2026) · Molecular & Cellular Toxicology · doi:10.1007/s13273-026-00604-y
Genistein–Butein Co-Treatment Suppresses Glycolytic Metabolism and Induces Apoptotic Signaling in PC-3 Prostate Cancer Cells
Cho, M. S., Lee, Y., Lee, S.-H., Nam, H.-S., & Lee, Y. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48030258
Regenerative Potential of Fibroblast Secretome: Keratinocyte Growth Factor (KGF) and Total Protein Effects on Senescent Cell Proliferation via Mek 1/2 Activation and Enhanced Collagen Type 1 Utilization
Riliani, M., Purwaningsih, E., Marsiati, H., Kusuma, I., Mukhtar, D., Hadi, R. S., & Rilianawati (2026) · The Open Biotechnology Journal · doi:10.2174/0118740707430933251216071858
Lycorine from Lycoris radiata induces M phase arrest in breast cancer by targeting miR-203a-3p-mediated MAPK signaling pathway
Zhou, S., Chen, G., Wang, B., Xue, Q., Wang, H. B., Liu, T., Chen, S., Wang, C., Qi, Z., Yu, M., et al. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.03.002
A computational rule-based model of MAPK/ERK system regulation
Kocieniewski, P., & Lipniacki, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-44353-3
ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability
Farnsworth, D., Naznin, F., Subramaniam, A., Sew, K., & Lockwood, W. W. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06084-6
The DYRK Family: A Key Regulator of Metabolic Homeostasis and Its Therapeutic Potential in Kidney Diseases
Liu, L., Qiao, P., Gan, Y., Fu, X., Huang, X., Sun, S., Gou, Y., Xia, W., Ma, F., & Liu, L. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70050
Manganese-tannic acid immunomodulators potentiate PDGFRβ CAR-T cell function for additive therapy against liver fibrosis
Wang, X., Duan, J., Cai, H., Liu, C., Ding, H., Xue, Y., Shengyuan, Y., Peng, S., Feng, Y., Qi, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114871
Therapeutic Effects of Akebia quinata Seeds Through Apoptosis and Immunogenic Cell Death in Non-Small Cell Lung Cancer
Jeong, M., Ha, I. J., Seo, C., Jeong, M.-K., Ahn, K. S., & Chun, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073114
GMFB promotes lung adenocarcinoma progression by activating the MAPK/ERK signaling pathway
Ma, L., Li, J., Yu, W., Li, R., & Si, L. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05535-9
Structurally diverse sesquiterpenoid glucoside esters from Cissampelopsis volubilis suppress triple-negative breast cancer via RAS-ERK signaling axis
Yan, Y., Wang, Y., Zhang, X., Ao, J., Zhang, Z., Wang, N., Hao, X., Ning, F., Zhang, L., & Tang, L. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109917
Comparative network pharmacology analysis of ketamine and xanomeline in major depressive disorder: Shared and distinct molecular mechanisms
Ding, X., Hashimoto, K., & Yang, J.-J. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111727
Research Progress of Cuproptosis in Orthopaedics: Opportunities and Challenges
Wang, C., & An, P. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71175
Development of dual A2AR/EGFR targeting pyrazoline–thiazole hybrids for restored apoptotic balance in colorectal cancer
Elzoghbi, N. Z., Kishk, S. M., Abadi, A. H., Salama, I., & Darwish, K. M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109985
Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy
Chi, F., Liu, C.-B., Li, J., Xia, X.-W., Hua, Q.-J., & Wang, W. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i5.118319
Deciphering skeletal muscle development: cellular heterogeneity and molecular regulatory networks from single-cell and spatial transcriptomic perspectives
Wang, X., Zhang, Y., Wei, H., Zhao, G., & Mu, R. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1827120
Constitutively active MEK1 expression driven by the myeloid-selective MRP8 promoter induces epithelial hyperplasia and papilloma formation
Zang, Y., Duan, R., Miranda, M. B., Rigatti, L. H., & Johnson, D. E. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154134
Advances in Quinazolinone‐Based Tumor‐Targeted Inhibitors
Li, J., Lv, S., Yang, B., Ran, R., Kong, Y., Cai, J., Nan, G., Jiang, S., & Dong, C. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71413
Organoids in biliary tract cancers: Advances in modeling strategies and translational applications
Yang, X.-H., Liu, D.-Y., Zhao, W., Yang, C.-W., Wang, J.-X., & Yao, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105468
Cancer Signaling Pathways and Cancer Biology
Nair, A., Prasad, A. P., Anand, A. V., Shyl, D., & Yesupatham, S. K. (2026) · Studies in Rhythm Engineering · doi:10.1007/978-981-95-8938-8_7
Deconvoluting the multi-faceted roles of alternative splicing events in cancer: From underlying mechanisms to innovative therapeutics
Hu, L., Wang, X., Fan, B., Zhao, Q., Zhong, Y., Lu, Y., Liao, M., Li, H., Fu, X., Wang, H., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.019
Protein Kinase C Epsilon: Dr. Jekyll and Mr. Hyde
Wells, A. T., & Lennartz, M. R. (2026) · Springer eBooks · doi:10.1007/978-3-031-55254-0_21-1
Exploring the putative role of EGFR in prostate cancer: Interactions with androgen and estrogen receptors
Gonçalves, G. M., Souza, D. S., Costa, C. R. M., Oliveira, M., Porto, C. S., & Vicente, C. M. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107101

Authors: Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X.
Affiliations: Sichuan University (CN)
Corresponding author: Wei, Xiawei
ORCID: Song, Yanlin
Bi, Zhenfei
Liu, Yu
Wei, Yuquan
Wei, Xiawei
Venue: Genes & Diseases
Publisher: Elsevier BV
Published: 2023-01
Volume: 10
Issue: 1
Pages: 76-88
ISSN: 2352-3042 (ISSN-L)
DOI: 10.1016/j.gendis.2022.05.006
PMC: PMC10066287
OpenAlex: W4280552157
Cited by: 212
References: 206
Citations by year: 2026: 52 · 2025: 77 · 2024: 58 · 2023: 23
FWCI: 4.17
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Genes & Diseases (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China (32122052)
Key Research and Development Program of Sichuan Province (2020YFS0553)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: RAS/MAPK pathway, targeted cancer therapy, RAS inhibitors, RAF inhibitors, MEK inhibitors, ERK inhibitor, combination therapy, RAS mutations, RAF mutations, clinical trials, tumor cell proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks